Literature DB >> 28138571

Ataxia telangiectasia mutated (ATM), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor?

Suk-Young Lee1, Sang Cheul Oh1.   

Abstract

Entities:  

Year:  2016        PMID： 28138571      PMCID： PMC5244801          DOI： 10.21037/tgh.2016.03.12

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  25 in total

1.  ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

Authors:  Chris T Williamson; Huong Muzik; Ali G Turhan; Alberto Zamò; Mark J O'Connor; D Gwyn Bebb; Susan P Lees-Miller
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

2.  Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

Authors:  Yung-Jue Bang; Seock-Ah Im; Keun-Wook Lee; Jae Yong Cho; Eun-Kee Song; Kyung Hee Lee; Yeul Hong Kim; Joon Oh Park; Hoo Geun Chun; Dae Young Zang; Anitra Fielding; Jacqui Rowbottom; Darren Hodgson; Mark J O'Connor; Xiaolu Yin; Woo Ho Kim
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

3.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

Authors:  Shuichi Hironaka; Shinya Ueda; Hirofumi Yasui; Tomohiro Nishina; Masahiro Tsuda; Takehiko Tsumura; Naotoshi Sugimoto; Hideki Shimodaira; Shinya Tokunaga; Toshikazu Moriwaki; Taito Esaki; Michitaka Nagase; Kazumasa Fujitani; Kensei Yamaguchi; Takashi Ura; Yasuo Hamamoto; Satoshi Morita; Isamu Okamoto; Narikazu Boku; Ichinosuke Hyodo
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

4.  Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer.

Authors:  Bin Kang; Rui-Fang Guo; Xiao-Hui Tan; Min Zhao; Zhuo-Bin Tang; You-Yong Lu
Journal:  Mutat Res       Date:  2007-09-01       Impact factor: 2.433

5.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 6.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

7.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

Authors:  Nuala McCabe; Nicholas C Turner; Christopher J Lord; Katarzyna Kluzek; Aneta Bialkowska; Sally Swift; Sabrina Giavara; Mark J O'Connor; Andrew N Tutt; Małgorzata Z Zdzienicka; Graeme C M Smith; Alan Ashworth
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

8.  In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs).

Authors:  Helge Otto; Pedro A Reche; Fernando Bazan; Katharina Dittmar; Friedrich Haag; Friedrich Koch-Nolte
Journal:  BMC Genomics       Date:  2005-10-04       Impact factor: 3.969

Review 9.  Chemotherapy induced DNA damage response: convergence of drugs and pathways.

Authors:  Derek Woods; John J Turchi
Journal:  Cancer Biol Ther       Date:  2013-02-04       Impact factor: 4.742

10.  Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.

Authors:  Rebecca A Dent; Geoffrey J Lindeman; Mark Clemons; Hans Wildiers; Arlene Chan; Nicole J McCarthy; Christian F Singer; Elizabeth S Lowe; Claire L Watkins; James Carmichael
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.